Medical Management of Glaucoma
- 29 October 1998
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (18) , 1298-1307
- https://doi.org/10.1056/nejm199810293391808
Abstract
Glaucoma is the leading cause of irreversible blindness in the world. It is estimated that by the year 2000, 66.8 million people will be affected, of whom 6.7 million will be blind in both eyes.1 Glaucoma is an optic neuropathy in which the axons of the optic nerve die and the plates of lamina cribrosa collapse, leading to loss of optic-nerve tissue and excavation, or “cupping,” of the ophthalmoscopically visible optic-nerve head. When sufficient axonal loss occurs, peripheral vision declines; loss of central vision occurs much later. Most forms of glaucoma are painless, and the loss of vision is insidious. . . .Keywords
This publication has 103 references indexed in Scilit:
- Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interactionPublished by American Medical Association (AMA) ,1995
- Improved lung function tests on changing from topical timolol: Non-selective beta-blockade impairs lung function tests in elderly patientsEye, 1993
- Adverse Pulmonary Effects of Topical ?? Blockers Used in the Treatment of GlaucomaJournal of Glaucoma, 1993
- Topical timolol and serum lipoproteins.British Journal of Ophthalmology, 1990
- Clinical Depression Associated With BetaxololAmerican Journal of Ophthalmology, 1986
- Respiratory Difficulties With BetaxololAmerican Journal of Ophthalmology, 1986
- Timolol-induced bronchospasm in asthmatic bronchitisPublished by American Medical Association (AMA) ,1981
- Timolol and myasthenia gravisPublished by American Medical Association (AMA) ,1979
- Renal Failure Associated With Acetazolamide Therapy for GlaucomaSouthern Medical Journal, 1975
- Increased intraocular pressure produced by prostaglandins E1 and E2 in the cat eyeExperimental Eye Research, 1970